Deal title Principal company Partner company Value (US$M) Start date

September

Clovis and 3BP to discover 3B-201 and 3B-202 plus radiopharmaceuticals for three targets using 3BP’s technology platform worldwide and the U.S., excluding Europe, Russia, Turkey, Israel 3B Pharmaceuticals GmbH Clovis Oncology Inc. $12.00 9/23/19
Adaptive Biotechnologies to use next-generation sequencing-based Clonoseq assay to assess minimal residual disease across multiple drug development programs within the Amgen hematology portfolio worldwide Adaptive Biotechnologies Corp. Amgen Inc. Payment unspecified 9/17/19
Adhex Pharma to manufacture Klaria Pharma's KL-00119 against migraine for clinical registration trial Adhex Pharma Klaria Pharma Holding Ab Payment unspecified 9/18/19
Adrexpharma to distribute Medipharm’s cannabis concentrate derivative products in Germany Adrexpharma GmbH Medipharm Labs Inc. Payment unspecified 9/24/19
Anchiano Therapeutics to acquire option rights to develop and commercialize ADT Pharmaceuticals' Pan-RAS inhibitor and PDE10/?-catenin inhibitor programs for cancer worldwide ADT Pharmaceuticals Anchiano Therapeutics $3.00 9/23/19
China National Biotec Group to distribute AAT's Algeness in mainland China Advanced Aesthetic Technologies Inc. China National Biotec Group Payment unspecified 9/19/19
Talem and Agonox to sign a letter of intent to form a joint venture for the development of antibody therapeutics to target T cell mediated anti-tumor activity worldwide Agonox Inc. Talem Therapeutics $720.00 9/24/19
Albany Molecular Research to manufacture Translate Bio's preclinical and clinical-stage programs Albany Molecular Research Inc. Translate Bio MA Inc. Payment unspecified 9/12/19
Horus expanded the agreement to distribute Alimera's Iluvien for diabetic macular edema in Belgium, the Netherlands and Luxembourg Alimera Sciences Inc. Horus Pharma SAS Payment unspecified 9/12/19
Alivamab Discovery Services to provide Alivamab Mouse technology to discover and deliver antibodies for Janssen Alivamab Discovery Services LLC Janssen Research & Development LLC Payment unspecified 9/16/19
Adhera Therapeutics to co-promote Allegis Pharmaceuticals' Nitrolingual Pumpspray to treat angina pectoris due to coronary artery disease Allegis Pharmaceuticals LLC Adhera Therapeutics Inc. Payment unspecified 9/6/19
Allied and CBD Group to form joint venture for distribution of cannabinoid-based cosmetic and natural health products in China, Hong Kong and throughout Asia Allied Corp. CBD Group Asia Ltd. Payment unspecified 9/11/19
Generex to sign binding letter of intent to acquire 51% of Altucell Altucell Inc. Generex Biotechnology Corp. Payment unspecified 9/9/19
American Cryostem and Biosolutions to conduct clinical study on Atcell for post-concussion syndrome American Cryostem Corp. Biosolutions Clinical Research Center LLC Payment unspecified 9/11/19
Apex to distribute Direct Biologics' mesenchymal stem cell derived exosomes Apex Biologix Direct Biologics LLC Payment unspecified 9/19/19
Applied Biomath and Verseau to deliver the pharmacology, pharmacokinetic and target engagement analysis for treatment of cancer Applied Biomath LLC Verseau Therapeutics Inc. Payment unspecified 9/3/19
Oxford Cannabinoid Technologies to acquire option rights to develop and commercialize Askat's CB2 receptor agonist, AAT-730 Askat Inc. Oxford Cannabinoid Technologies Payment unspecified 9/20/19
Aslan and Bukwang to form joint venture Jaguahr Therapeutics to develop aryl hydrocarbon receptor antagonists Aslan Pharmaceuticals Pte. Ltd. Bukwang Pharmaceutical Co. Ltd. $5.00 9/30/19
Theragnostics to use Astrazeneca's intellectual property rights to develop radionuclide-labelled PARP inhibitors against cancer Astrazeneca plc Theragnostics Ltd. Payment unspecified 9/5/19
Atomwise and Hansoh Pharmaceutical to design and discover eleven undisclosed target proteins in multiple therapeutic areas using artificial intelligence technology Atomwise Hansoh Pharmaceutical Group Company Ltd. $1,500.00 9/11/19
Atomwise and Oncostatyx to establish a joint venture to discover and develop KDM5B inhibitors for triple-negative breast cancer Atomwise Oncostatyx LLC Payment unspecified 9/10/19
Atomwise and Atropos to launch joint venture for discovery of senescence modulating small molecules for cancer Atomwise Atropos Therapeutics Inc. Unknown 9/11/19
Poly Pharmaceuticals to co-promote Aytu Bioscience's Tuzistra XR in the U.S. Aytu Bioscience Inc. Poly Pharmaceuticals Inc. Payment unspecified 9/4/19
BC Platforms to provide clinical and genomic data management solution to Debiopharm oncology products BC Platforms Debiopharm SA Payment unspecified 9/18/19
Be The Match to support clinical trials of Celyad's allogeneic CAR-T therapies for cancer Be The Match Biotherapies Celyad SA Payment unspecified 9/10/19
Beam and Prime Medicine to research and develop prime editing technology to treat sickle cell disease and single base transition mutations in the U.S. Beam Therapeutics Inc. Prime Medicine Inc. Payment unspecified 9/30/19
R-Pharm to sign letter of intent to develop and commercialize Beijing Health's nonavalent HPV vaccine against HPV infections and cervical cancer in Russia Beijing Health Guard Biotechnology Co. Ltd. R-Pharm Payment unspecified 9/5/19
Novartis to use Benevolentai's technology to interrogate clinical trial and experimental data for oncology assets Benevolentai Ltd. Novartis Pharma AG Payment unspecified 9/5/19
Vaxil Bio to use BGN's E-selectin targeted polymer to develop and commercialize targeted cancer therapy worldwide BGN Technologies Vaxil Biotherapeutics Ltd. Payment unspecified 9/23/19
Bioglan to manufacture Follicum's FOL-005 against hair loss for phase II clinical trial Bioglan Pharmaceuticals Co. Follicum AB Payment unspecified 9/26/19
Avanos to develop and commercialize Bioq Pharma's non-opioid post-operative pain pharmaceutical product in the U.S., Canada and Mexico Bioq Pharma Inc. Avanos Medical Inc. Payment unspecified 9/17/19
Oncoheroes Biosciences to develop and commercialize Boehringer's volasertib for the treatment of pediatric cancer indications worldwide Boehringer Ingelheim International GmbH Oncoheroes Biosciences Inc. Payment unspecified 9/16/19
Biomotiv and BMS to form and fund new companies to develop novel therapeutics against multiple diseases, with an acquisition option for BMS Bristol-Myers Squibb Co. Biomotiv LLC Payment unspecified 9/4/19
Medicure International acquires the U.S. and Canadian marketing rights of Cadila Healthcare's Zypitamag (pitavastatin) Cadila Healthcare Ltd. Medicure International Inc. $7.00 9/30/19
Caredx and Nanostring to develop Histomap for identifying allograft rejection in transplant biopsy tissue Caredx Inc. Nanostring Technologies Inc. Payment unspecified 9/24/19
Oxford Nanopore to use Caribou's CRISPR-Cas9 related intellectual property for nanopore sequencing worldwide Caribou Biosciences Inc. Oxford Nanopore Ltd. Payment unspecified 9/19/19
Phio Pharmaceuticals to evaluate its self-delivering RNAi compounds to synergistically modify Carisma's chimeric antigen receptor macrophages for use in cancer Carisma Therapeutics Inc. Phio Pharmaceuticals Corp. Payment unspecified 9/9/19
Catalent to manufacture Acura's LTX-03 tablets for pain Catalent Inc. Acura Pharmaceuticals Inc. Payment unspecified 9/9/19
Catalent to manufacture and supply Minerva's roluperidone for the treatment of schizophrenia Catalent Inc. Minerva Neurosciences Inc. $8.43 9/18/19
Takeda to use Cerveau's MK-6240-[18F] in PET scanning for neurodegenerative diseases Cerveau Technologies Inc. Takeda Pharmaceutical Co. Ltd. Payment unspecified 9/27/19
An undisclosed company to distribute Cesca Therapeutics' X-Series products worldwide, excluding China Cesca Therapeutics Inc. Undisclosed $2.00 9/9/19
Clinigen to distribute Cheplapharm's Etopophos and Vepesid against cancer in Australia and New Zealand Cheplapharm Arzneimittel GmbH Clinigen Group plc Payment unspecified 9/1/19
Symbio to develop, manufacture and commercialize Chimerix’s brincidofovir worldwide for all human indications, excluding smallpox Chimerix Inc. Symbio Pharmaceuticals Ltd. $185.00 9/30/19
Mundipharma to develop and commercialize Cidara's intravenous rezafungin and option for subcutaneous rezafungin for fungal infections worldwide, excluding the U.S. and Japan Cidara Therapeutics Inc. Mundipharma International Corp. Ltd. $615.76 9/3/19
Kalbe to sell CJ Healthcare’s K-CAB for gastroesophageal reflux in Indonesia CJ Healthcare Corp. PT Kalbe Farma Tbk Payment unspecified 9/18/19
Convenience Valet to distribute Medterra's cannabinoid products in the U.S. Convenience Valet Medterra CBD LLC Payment unspecified 9/26/19
Wize Pharma to develop Copernicus Therapeutics' WP-REP1, an ophthalmic nonviral gene therapy, for the treatment of choroideremia worldwide Copernicus Therapeutics Inc. Wize Pharma Inc. Payment unspecified 9/4/19
Fujifilm exercised its option with Cynata Therapeutics for a worldwide license to develop and commercialize CYP-001 for graft-versus-host disease Cynata Therapeutics Ltd. Fujifilm Corp. Payment unspecified 9/17/19
Dariohealth and Dance Biopharm to integrate mist smart inhaler with digital platform for chronic disease patients Dariohealth Corp. Dance Biopharm Inc. Payment unspecified 9/11/19
Alexion Pharmaceuticals to develop and commercialize Eidos' AG-01 for TTR amyloidosis in Japan Eidos Therapeutics Inc. Alexion Pharmaceuticals Inc. $50.00 9/9/19
Thermo Fisher to develop companion diagnostic using Oncomine test to identify RET-altered non-small-cell lung cancer and thyroid cancer patients for Eli Lilly's LOXO-292 Eli Lilly and Co. Thermo Fisher Scientific Inc. Payment unspecified 9/2/19
Raqualia and Epigeneron to discover, with an option to develop and commercialize therapeutics using Locus-specific ChIP for idiopathic pediatric nephrosis syndrome Epigeneron Inc. Raqualia Pharma Inc. Payment unspecified 9/17/19
Evotec and Takeda Pharmaceutical to develop five small molecule discovery programs against oncology, gastroenterology, neuroscience and rare diseases Evotec SE Takeda Pharmaceutical Co. Ltd. $850.00 9/24/19
Bluebird bio to conduct clinical studies for Forty Seven's FSI-174 and magrolimab as conditioning regimen prior to ex vivo lentiviral vector hematopoietic stem cell gene therapy Forty Seven Inc. Bluebird bio Inc. Payment unspecified 9/30/19
Fujitsu and Peptidream to discover and develop peptide drugs using Digital Annealer Fujitsu Ltd. Peptidream Inc. Payment unspecified 9/20/19
Futura Medical and Cbderma to form joint venture to develop Dermasys for cannabidiol delivery Futura Medical plc Cbderma Technology Ltd. Payment unspecified 9/10/19
Gaba Therapeutics and Atai Life to develop GRX-917 for mood disorders, including anxiety and depression Gaba Therapeutics Atai Life Sciences AG Payment unspecified 9/20/19
Adalta and GE Healthcare to develop i-bodies as diagnosis in immunotherapy General Electric Co. Adalta Pty Ltd. Payment unspecified 9/16/19
DAS Therapeutics acquires GT Biopharma's GTB-004 for myasthenia gravis GT Biopharma Inc. DAS Therapeutics Inc. $6.20 9/19/19
Silanes to launch Hanmi's Amosartan plus and Amosartan Q for dyslipidemia and hypertension in Latin America Hanmi Pharmaceutical Co. Ltd. Laboratorios Silanes SA De CV Payment unspecified 9/11/19
Happify and Sanofi to develop digital therapeutics for multiple sclerosis worldwide Happify Inc. Sanofi SA Payment unspecified 9/17/19
Blanver to commercialize Helsinn's Pracinostat for acute myeloid leukemia in South America Helsinn Healthcare SA Blanver Farmoquimica Ltda Payment unspecified 9/2/19
Pacific Alliance Group to acquire a majority stake in Hisun Bioray Bio-pharmaceutical Hisun Bioray Bio-pharmaceutical Co. Ltd. Pacific Alliance Group $556.97 9/4/19
Batavia to use Horizon's GS knockout CHO K1 cell line expression system to develop antibody expressing cell lines Horizon Discovery Group plc Batavia Biosciences BV Payment unspecified 9/3/19
Glenmark to use Horizon's GS knockout CHO K1 cell line expression system to manufacture biotherapeutics Horizon Discovery Group plc Glenmark Pharmaceuticals Ltd. Payment unspecified 9/30/19
Novartis and IFM Due to research and develop cGAS/STING programs against inflammatory and autoimmune diseases, with an option to acquire IFM Due IFM Due Novartis AG $840.00 9/5/19
Ildong to market Glaxosmithkline's Relenza for the treatment of influenza A and B virus infections Il Dong Pharmaceutical Co. Ltd. Glaxosmithkline plc Payment unspecified 9/6/19
I-Mab Biopharma and Junshi Biosciences to evaluate the combination of TJD-5 with toripalimab to treat cancers in China I-Mab Biopharma Co. Ltd. Shanghai Junshi Biosciences Co. Ltd. Payment unspecified 9/10/19
I-Mab and Merck to evaluate the combination of TJC-4 and Keytruda for multiple cancer types in a phase I clinical trial I-Mab Biopharma Co. Ltd. Merck & Co. Inc. Payment unspecified 9/23/19
Immunomedics and Roche Holding to evaluate the safety and efficacy of the combination of Tecentriq (atezolizumab) and sacituzumab govitecan as a front-line treatment of patients with metastatic or inoperable locally advanced triple-negative breast cancer Immunomedics Inc. Roche Holding AG Payment unspecified 9/30/19
Immunomedics and GBG Forschungs to develop sacituzumab govitecan as a treatment for newly diagnosed breast cancer patients Immunomedics Inc. GBG Forschungs-GmbH Payment unspecified 9/30/19
Adhera to use Indegene's co-commercialization model to advance the commercialization of Prestalia in the U.S. Indegene Adhera Therapeutics Inc. Payment unspecified 9/10/19
Selexis to commercialize Inflamacore's IC-100 for multiple inflammatory conditions Inflamacore LLC Selexis SA Payment unspecified 9/5/19
Inflammasome and Boehringer Ingelheim to develop up to three therapies using intravitreal drug delivery technology for retinal diseases Inflammasome Therapeutics Inc. Boehringer Ingelheim International GmbH $160.00 9/20/19
Btcp Pharma acquires Insys’ Subsys for cancer pain management Insys Therapeutics Inc. Btcp Pharma LLC $20.00 9/26/19
Tris to market, sell and distribute Intellipharmaceutics' Desvenlafaxine Succinate ER in the U.S. Intellipharmaceutics International Inc. Tris Pharma Inc. Payment unspecified 9/5/19
Roslin Technologies to use Ips Academia Japan's patents related to iPS cell-derived cells Ips Academia Japan Inc. Roslin Technologies Ltd. Payment unspecified 9/4/19
Astrazeneca amended the agreement to obtain exclusive rights to develop, manufacture and commercialize Ironwood Pharmaceuticals' linaclotide in China Ironwood Pharmaceuticals Inc. Astrazeneca plc Payment unspecified 9/16/19
Duchembio to develop and commercialize Isotopen's Solucin targeted radionuclide therapy for neuroendocrine tumors in South Korea Isotopen Technologien München AG Duchembio Co. Ltd. Payment unspecified 9/2/19
Simcere and JW Pharmaceutical to develop and commercialize URC-102 against gout in China, Hongkong and Macau JW Pharmaceutical Corp. Simcere Pharmaceutical Group Payment unspecified 9/27/19
Kahr Medical and Roche to evaluate the combination of DSP-107 with atezolizumab in phase I/II study to treat non-small-cell lung cancer Kahr Medical Ltd. Roche Holding AG Payment unspecified 9/9/19
Kamada extended its strategic supply agreement with Takeda Pharmaceutical for Glassia through 2021, receiving royalties of 12% on net sales through August 2025 and 6% afterward until 2040 Kamada Ltd. Takeda Pharmaceutical Ltd. Payment unspecified 9/4/19
Healthcare Royalty Partners to purchase Karyopharm's royalty to develop and commercialize Xpovio against heavily pretreated multiple myeloma worldwide Karyopharm Therapeutics Inc. Healthcare Royalty Partners $150.00 9/16/19
Boston Pharmaceuticals to develop and commercialize Kempharm's serdexmethylphenidate and d-methylphenidate based therapeutics for attention deficit and hyperactivity disorder worldwide Kempharm Inc. Boston Pharmaceuticals $493.00 9/3/19
Lexicon Pharmaceuticals to receive $260M for termination of the alliance with Sanofi for development and commercialization of Zynquista Lexicon Pharmaceuticals Inc. Sanofi SA $260.00 9/12/19
Huons to develop and commercialize Lipac's TSD-001 for various indications Lipac Oncology LLC Huons Co. Ltd. Payment unspecified 9/16/19
Lonza to manufacture Celltrion Healthcare's Remsima for autoimmune diseases, including Crohn’s disease and rheumatoid arthritis Lonza Group AG Celltrion Healthcare Co. Ltd. Payment unspecified 9/3/19
Cayman to use Lubrigreen Biosynthetics' patents related to fatty acid hydroxy fatty acid products Lubrigreen Biosynthetics LLC Cayman Chemical Co. Inc. Payment unspecified 9/3/19
Boehringer Ingelheim and Lupin to develop and commercialize LNP-3794 and KRAS inhibitor combination drug to treat KRAS-driven cancers Lupin Ltd. Boehringer Ingelheim International GmbH $720.00 9/4/19
Lupin divests injectables business to Neopharma in Japan Lupin Ltd. Neopharma Payment unspecified 9/30/19
BJ Bioscience and Medx to develop BJ-001 companion diagnostic for cancer Medx (Suzhou) Translational Medicine Co. Ltd. BJ Bioscience Inc. Payment unspecified 9/4/19
Grunenthal to develop and commercialize Mesoblast’s MPC-06-ID for chronic low back pain in Europe and Latin America Mesoblast Ltd. Grunenthal GmbH $1,150.00 9/9/19
Mitsubishi to co-promote Santen’s Alesion 0.05% ophthalmic solution in Japan Mitsubishi Tanabe Pharma Corp. Santen Pharmaceutical Co. Ltd. Payment unspecified 9/20/19
Daiichi Sankyo to commercialize Mitsubishi Tanabe's edaravone for amyotrophic lateral sclerosis in Brazil Mitsubishi Tanabe Pharma GmbH Daiichi Sankyo Co. Ltd. Payment unspecified 9/17/19
Taisho to develop and commercialize Moberg's MOB-015 against onychomycosis in Japan Moberg Pharma AB Taisho Pharmaceutical Co. Ltd. $50.00 9/30/19
Mylan to distribute Eisai's Teceris for metastatic breast cancer in India Mylan NV Eisai Pharmaceuticals India Pvt. Ltd. Payment unspecified 9/20/19
Hillstream to acquire Nanoproteagen's immuno-oncology assets, including HSB-114 and Quatramer technology Nanoproteagen Inc. Hillstream Biopharma Inc. Payment unspecified 9/10/19
Eisai and Nichi-Iko Pharmaceutical to collaborate for the generic pharmaceutical business in China Nichi-Iko Pharmaceutical Co. Ltd. Eisai Co. Ltd. Payment unspecified 9/30/19
Nissan and Veritas to discover small molecule drugs targeting nucleic acids Nissan Chemical Corp. Veritas In Silico Inc. Payment unspecified 9/6/19
Amplyx acquired worldwide rights of Novartis’ MAU-868 for BK viral disease Novartis Pharmaceuticals Corp. Amplyx Pharmaceuticals Inc. Payment unspecified 9/16/19
Cansino Biologics to develop, manufacture and commercialize Ocugen’s OCU-400 for inherited retinal diseases in greater China Ocugen Inc. Cansino Biologics Inc. Payment unspecified 9/30/19
Optinose to grant Currax certain patent rights to market Onzetra Xsail in the U.S., Canada and Mexico Optinose AS Currax Pharmaceuticals LLC $5.48 9/25/19
Or-Genix and Fission Labs to develop molecule to formulate products for blemishes, oily skin and alopecia to be sold in Latin America Or-Genix Therapeutics Inc. Fission Labs Latam Payment unspecified 9/30/19
Xoma acquires royalty interest in six clinical stage assets from Palobiofarma Palobiofarma SL Xoma Corp. $10.00 9/26/19
Peptidream and JSR to identify peptides applicable to the affinity chromatography process Peptidream Inc. JSR Corp. Payment unspecified 9/20/19
Hanmi Pharmaceutical to use Phanes' antibody sequences to discover and develop bi and multi-specific antibodies for oncology worldwide Phanes Therapeutics Hanmi Pharmaceutical Co. Ltd. Payment unspecified 9/24/19
Pharmaceutics to manufacture and supply Sagent's generic Fulvestrant Injection 250mg/5ml against breast cancer Pharmaceutics International Inc. Sagent Pharmaceuticals Inc. Payment unspecified 9/23/19
Pharmeco to produce and distribute Roche's emicizumab for hemophilia A in Russia Pharmeco Roche Holding AG Payment unspecified 9/25/19
Sandoz to commercialize Polpharma Biologics' natalizumab biosimilar for relapsing-remitting multiple sclerosis worldwide Polpharma Biologics SA Sandoz AG Payment unspecified 9/3/19
Bayer to use Probiogen's Glymaxx to develop undisclosed antibody candidate for oncology Probiogen AG Bayer AG Payment unspecified 9/10/19
Reprocell to distribute Neucyte's induced pluripotent stem cell-derived glutamatergic and gabaergic induced neurons in North America and Europe Reprocell Inc. Neucyte Inc. Payment unspecified 9/25/19
Ribometrix and Vertex to develop RNA-targeted small molecule therapeutic candidates for serious diseases worldwide Ribometrix Inc. Vertex Pharmaceuticals Inc. $720.00 9/30/19
Askbio acquires Rovermed's nanotechnology cargo delivery platform assets Rovermed Biosciences LLC Asklepios Biopharmaceutical Inc. Payment unspecified 9/17/19
Mindmed acquires Savant's 18-MC to treat drug addiction Savant HWP Inc. Mind Medicine Inc. Payment unspecified 9/16/19
Astrazeneca to use Schrodinger's advanced computing platform to accelerate the drug discovery Schrodinger LLC Astrazeneca plc Payment unspecified 9/4/19
Takeda and Schrodinger expanded the collaboration to discover multi-targets for various diseases using computational silico platform Schrodinger LLC Takeda Pharmaceuticals Co. Ltd. Payment unspecified 9/5/19
Undisclosed pharmaceutical company to use Secarna’s Lnaplus oligonucleotides in oncology research Secarna Pharmaceuticals GmbH & Co. KG Undisclosed Payment unspecified 9/10/19
Selexis to provide cell line expression technologies to develop Zyversa's IC-100 for multiple inflammatory conditions Selexis SA Zyversa Therapeutics Inc. Payment unspecified 9/5/19
Sengine and Atomwise to form joint venture to accelerate the oncology drug discovery using platform technologies Sengine Precision Medicine Inc. Atomwise Payment unspecified 9/10/19
Kalbe Genexine to develop and commercialize Shanghai Henlius' HLX-10 in 10 countries Shanghai Henlius Biotech Co. Ltd. Kalbe Genexine Biologics $682.00 9/12/19
Siegfried to manufacture and supply Aprea Therapeutics' APR-246 against cancer Siegfried Hameln GmbH Aprea Therapeutics AB Payment unspecified 9/19/19
Solti to conduct clinical research on Context Therapeutics' Apristor in breast cancer patients Solti Breast Cancer Research Group Context Therapeutics LLC Payment unspecified 9/16/19
Soricimed and IAG to develop SOR-C13 for solid cancer tumors Soricimed Biopharma Inc. Image Analysis Group Payment unspecified 9/5/19
Sparsha to manufacture Nemaura Pharma's transdermal therapeutic systems in the U.S., Canadian and Latin American markets Sparsha Nemaura Pharma Ltd. Payment unspecified 9/27/19
Terrascend to commercialize Syqe Medical's Syqe Inhaler in Canada Syqe Medical Ltd. Terrascend Corp. Payment unspecified 9/16/19
Nippon Shokubai to develop TAK-Circulator’s TAKC-02 for steroid resistant severe asthma Tak-Circulator Co. Ltd. Nippon Shokubai Co. Ltd. Payment unspecified 9/10/19
Genmab and Tempus to advance disease targets and biomarkers for generating treatments in oncology Tempus Inc. Genmab A/S Payment unspecified 9/9/19
Johnson & Johnson exercised commercial option to license and advance Teneobio's undisclosed multispecific product for development in an oncology indication in return for milestones and royalties Teneobio Inc. Johnson & Johnson Payment unspecified 9/30/19
Terumo to manufacture Teribone 28.2 microg for Asahi Kasei Pharma to treat osteoporosis with high risk of fractures Terumo Corp. Asahi Kasei Pharma Corp. Payment unspecified 9/20/19
Super-Pharm to purchase 50% stake in Teva’s pharmaceutical preparations business to form a new company Teva Pharmaceutical Industries Ltd. Super Pharm Ltd. Payment unspecified 9/1/19
Thermo Fisher to develop, commercialize and manufacture Frontier's 3-BNC-117 for HIV infection Thermo Fisher Scientific Inc. Frontier Biotechnologies Inc. Payment unspecified 9/26/19
Zymeworks to use Trianni's mouse technology to discover and develop fully human monoclonal antibodies Trianni Inc. Zymeworks Inc. Payment unspecified 9/10/19
Neucyte to develop and commercialize Trillium's preclinical compound for treatment of refractory epilepsy in the form of Dravet syndrome and related disorders worldwide Trillium Therapeutics Inc. Neucyte Inc. Payment unspecified 9/24/19
Glycotope to use Tubulis' antibody drug conjugate (ADC) technologies, Tub-tag to identify the ADC candidates Tubulis GmbH Glycotope GmbH Payment unspecified 9/11/19
Antibody technology company to evaluate Scancell's pipeline of monoclonal antibodies targeting TaGs using Avidimab technology against cancer Undisclosed Scancell Ltd. Payment unspecified 9/4/19
Grunenthal and Uniquest to develop non-opioid drug therapies for chronic neuropathic pain Uniquest Pty Ltd. Grunenthal GmbH Payment unspecified 9/3/19
Can-Fite and Univo Pharmaceuticals to develop cannabinoid-based pharmaceuticals and assays for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases Univo Pharmaceuticals Ltd. Can-Fite Biopharma Ltd. $0.50 9/10/19
VBI Vaccines and GSK to evaluate the combination of VBI-1901 with AS01B adjuvant in phase I/IIa clinical study against recurrent glioblastoma VBI Vaccines Inc. Glaxosmithkline plc Payment unspecified 9/10/19
Alytas to use Velabs Therapeutics' microfluidic-based technology to develop immune-based therapy against obesity worldwide Velabs Therapeutics GmbH Alytas therapeutics GmbH Payment unspecified 9/3/19
Widetrial further agreed to provide expanded access programs to Mateon Therapeutics to develop OT-101 for pancreatic cancer Widetrial Inc. Mateon Therapeutics Inc. Payment unspecified 9/9/19
China Pharma to enter memorandum of understanding to develop World Health Advanced Technologies' Enercel in China World Health Advanced Technologies Ltd. China Pharma Holdings Inc. Payment unspecified 9/11/19
X-Chem and Maruho to discover and develop compounds for novel targets against human diseases worldwide X-Chem Inc. Maruho Co. Ltd. Payment unspecified 9/4/19
Flexion to develop and commercialize Xenon's XEN-402 with FX-301 for post-operative pain worldwide Xenon Pharmaceuticals Inc. Flexion Therapeutics Inc. $127.75 9/9/19
Merck and Y-Trap to develop and commercialize antibody-ligand traps for cancer immunotherapy Y-Trap Inc. Merck KGaA Payment unspecified 9/19/19

 

 

Deal title Principal company Partner company Value (US$M) Start date

October

3P to develop and manufacture Zhittya’s FGF-1 for clinical studies against Parkinson’s disease 3P Biopharmaceuticlas SL Zhittya Regenerative Medicine Inc. Payment unspecified 10/21/19
4D pharma and Merck to discover and develop live biotherapeutics as vaccines in up to three undisclosed indications 4D pharma plc Merck & Co. Inc. $1,047.50 10/8/19
Reata Pharmaceuticals agreed to pay Abbvie $330M plus royalties to reacquire ex-U.S. development, manufacturing and commercialization rights for the Nrf2 activators bardoxolone methyl and omaveloxolone, as well as other next-generation candidates Abbvie Inc. Reata Pharmaceuticals Inc. $330.00 10/10/19
Disc Medicine to develop Abbvie's series of hemojuvelin antagonist monoclonal antibodies for anemia worldwide Abbvie Inc. Disc Medicine Payment unspecified 10/29/19
Abzena to manufacture Sonnet Biotherapeutics' SON-1010 for solid tumor Abzena plc Sonnet Biotherapeutics Inc. Payment unspecified 10/22/19
EPI Health to acquire Aclaris Therapeutics' worldwide intellectual property rights related to Rhofade for the treatment persistent facial erythema Aclaris Therapeutics Inc. EPI Health LLC $55.00 10/10/19
Emerge Health to distribute and commercialize Adamis Pharmaceuticals' Symjepi (epinephrine) in Australia and New Zealand Adamis Pharmaceuticals Corp. Emerge Health Pty. Ltd. Payment unspecified 10/1/19
Indivior to provide Addex Therapeutics with an additional $800,000 to accelerate research progress in their collaboration to develop further oral gamma-aminobutyric acid subtype B positive allosteric modulator compounds for the treatment of addiction Addex Therapeutics Ltd. Indivior plc $0.80 10/8/19
Pfizer to develop Akcea Therapeutics' AKCEA-ANGPTL3-LRx against cardiovascular and metabolic diseases worldwide Akcea Therapeutics Inc. Pfizer Inc. $1,550.00 10/7/19
Aldevron to provide GMP manufacturing capacity for PTC's gene therapy against Friedreich ataxia and Angelman syndrome programs Aldevron LLC PTC Therapeutics Inc. Payment unspecified 10/7/19
Pharmbio Korea to commercialize Alvogen's Teriparatide for osteoporosis in South Korea Alvogen Inc. Pharmbio Korea Co. Ltd. Payment unspecified 10/21/19
Kamada to commercialize Alvogen's Teriparatide for osteoporosis in Israel Alvogen Inc. Kamada Ltd. Payment unspecified 10/21/19
Jamp Pharma to commercialize Alvogen's Teriparatide for osteoporosis in Canada Alvogen Inc. Jamp Pharma Corp. Payment unspecified 10/21/19
Emerald Organic Growth to develop and commercialize Amarantus Biosciences' eltoprazine, engineered skin substitute, mesencephalic astrocyte-derived neurotrophic factor against Attention-deficit/hyperactivity disorder, Parkinson’s, skin burns and vision loss worldwide Amarantus Bioscience Holdings Inc. Emerald Organic Products Inc. $100.00 10/24/19
Novocodex to develop and commercialize Ambrx's ARX-305 for CD70-positive cancers in China Ambrx Inc. Novocodex Biopharmaceuticals Co. Ltd. Payment unspecified 10/23/19
Amerisourcebergen to provide dispensing and distribution services to Karyopharm's Xpovio against relapsed or refractory multiple myeloma Amerisourcebergen Drug Corp. Karyopharm Therapeutics Inc. Payment unspecified 10/1/19
Beigene and Amgen to develop and commercialize oncology drugs worldwide, including China Amgen Inc. Beigene Co. Ltd. $3,984.00 10/31/19
Stallergenes and Anergis to evaluate the effects of the second-generation virosome-based continuous overlapping peptides allergen immunotherapy from Greer in a therapeutic model of birch allergy in mice Anergis SA Stallergenes Greer plc Payment unspecified 10/17/19
Applied Genetic Technologies and Otonomy to co-develop and co-commercialize AAV-based gene therapy for sensorineural hearing loss Applied Genetic Technologies Corp. Otonomy Inc. Payment unspecified 10/1/19
Puretech Health plc acquired the remaining 10% minority interests in Ariya Therapeutics Inc. Ariya Therapeutics Inc. Puretech Health plc Payment unspecified 10/1/19
Editas and Asklepios to develop AAV vector delivery of genome editing medicines to treat neurological diseases Asklepios Biopharmaceutical Inc. Editas Medicine Inc. Payment unspecified 10/15/19
ASM Aerosol to provide manufacturing and supply services for Foamix’s Amzeeq and FMX-103 ASM Aerosol-Service AG Foamix Pharmaceuticals Ltd. Payment unspecified 10/21/19
Daiichi to acquire Astellas' Nasea, Perdipine and Oldeca for emesis and hypertension in Korea, Thailand, the Philippines, Indonesia, China and Taiwan Astellas Pharma Inc. Daiichi Sankyo Co. Ltd. $88.44 10/15/19
Cheplapharm Arzneimittel to commercialize Astrazeneca's Losec worldwide, excluding China, Japan, the U.S. and Mexico Astrazeneca plc Cheplapharm Arzneimittel GmbH $276.00 10/1/19
Imaginab and Astrazeneca to evaluate the utility and value of Imaginab's CD8 ImmunoPET technology in immuno-oncology drug development Astrazeneca plc Imaginab Inc. Payment unspecified 10/14/19
Cheplapharm to commercialize Astrazeneca's Seroquel and Seroquel XR for schizophrenia and bipolar disorder in Europe and Russia Astrazeneca plc Cheplapharm Arzneimittel GmbH $239.00 10/30/19
Telix Pharmaceuticals and Aushealth to develop new therapeutics using molecularly targeted radiation platform for lung and ovarian cancer Aushealth Telix Pharmaceuticals Ltd. $20.97 10/29/19
Avacta to use its Affimer technology with pyrrolobenzodiazepine-based warhead and linker technologies to generate drug conjugates for cancer Avacta Group plc ADC Therapeutics SA Payment unspecified 10/10/19
Aytu and Validus to co-promote Zolpimist for insomnia in the U.S. Aytu Bioscience Inc. Validus Pharmaceuticals LLC Payment unspecified 10/1/19
Ginkgo Bioworks to use Berkeley Lights' optofluidic platform to develop development workflow for synthetic biology products Berkeley Lights Inc. Ginkgo Bioworks $150.00 10/1/19
Bioglan to manufacture Lobsor Pharmaceuticals' Lecigon for Parkinson's disease in Europe Bioglan AB Lobsor Pharmaceuticals AB Payment unspecified 10/2/19
Allievex to develop Biomarin's tralesinidase alfa for MPS IIIB or Sanfilippo Syndrome Type B Biomarin Pharmaceutical Inc. Allievex Corp. Payment unspecified 10/23/19
Basf and Biomillenia to identify dermocosmetic active ingredients for skin health Biomillenia SAS Basf SE Payment unspecified 10/7/19
Q Biomed to enter settlement agreement with Bionucleonics to complete the outright acquisition of the non-opioid cancer bone pain drug strontium-89 chloride USP Bionucleonics Inc. Q Biomed Inc. Payment unspecified 10/2/19
Ipsen to develop and commercialize Blueprint's BLU-782 for fibrodysplasia ossificans progressiva worldwide Blueprint Medicines Corp. Ipsen $535.00 10/16/19
Cycle Pharmaceuticals to use Catalent's Zydis technologies to develop formulations targeting rare metabolic and neurological disorders Catalent Inc. Cycle Pharmaceuticals Ltd. Payment unspecified 10/31/19
Celmatix and Evotec to discover and develop preclinical programs for women's reproductive health Celmatix Inc. Evotec SE Payment unspecified 10/9/19
Aytu Bioscience acquires Cerecor's Pediatric Portfolio Cerecor Inc. Aytu Bioscience Inc. $43.00 10/10/19
Cesca and Healthbanks to form joint venture Immunecyte Life Sciences to commercialize CAR-Txpress for use in immune cell banking, cell-based contract development and manufacturing services Cesca Therapeutics Inc. Healthbanks Biotech USA Inc. Payment unspecified 10/22/19
Bausch Health to develop and commercialize Clearside's Xipere for macular edema associated with uveitis in the U.S. and Canada Clearside Biomedical Inc. Bausch Health Companies Inc. $20.00 10/23/19
Regenxbio to pay $2M for exercising its option to license Clearside Biomedical's SCS Microinjector Clearside Biomedical Inc. Regenxbio Inc. $2.00 10/30/19
Clinigen Group launched a managed access program to provide Progenics Pharmaceuticals' Azedra (iobenguane I 131) outside the U.S. Clinigen Group plc Progenics Pharmaceuticals Inc. Payment unspecified 10/10/19
Cmab Biopharma to provide development and manufacturing services for BJ Bioscience's BJ-005 to suppport IND requirements of China and the US Cmab Biopharma Inc. BJ Bioscience Inc. Payment unspecified 10/11/19
Cobra Biologics to manufacture Combigene’s CG-01 for clinical studies in epilepsy and commercial production Cobra Biologics Holding AB Combigene Ab $0.16 10/14/19
Kitov Pharma amended the marketing and distribution agreement with Coeptis Pharmaceuticals for commercialization of Consensi for the treatment of pain caused by osteoarthritis and amlodipine besylate for hypertension Coeptis Pharmaceuticals Inc. Kitov Pharma Ltd. $99.50 10/11/19
Redhill Biopharma to commercialize Cosmo's Aemcolo for Traveler’s Diarrhea in the U.S. Cosmo Pharmaceuticals NV Redhill Biopharma Ltd. $112.00 10/18/19
Takeda Pharmaceutical acquired an exclusive worldwide license to develop and commercialize CNP-101/TAK-101 from Cour Pharmaceutical Development Cour Pharmaceutical Development Co. Inc. Takeda Pharmaceutical Co. Ltd. $420.00 10/22/19
Sundial Growers to use Crescita's transdermal delivery technologies to develop topicals containing cannabis and hemp worldwide Crescita Therapeutics Inc. Sundial Growers Inc. Payment unspecified 10/28/19
Cryoport to provide temperature-controlled logistics solutions to Adaptimmune's ADP-A2M4CD8 to treat cancer Cryoport Inc. Adaptimmune Therapeutics plc Payment unspecified 10/9/19
Servier acquires CTI Biopharma's Pixuvri CTI Biopharma Corp. Servier Payment unspecified 10/1/19
Axcella Health to use Cytoo's Myoscreen for development of novel Axa candidates against dysregulated muscle metabolism Cytoo SA Axcella Health Inc. Payment unspecified 10/23/19
Parexel and Datavant to enable the connection of real-world data across all clinical trials by combining standard data workflow with connectivity technology Datavant Parexel International Payment unspecified 10/9/19
Dicerna and Roche to develop DCR-HBVS and oligonucleotide therapeutics for HBV infection worldwide Dicerna Pharmaceuticals Inc. Roche Holding AG $1,670.00 10/30/19
Elevar and Neopharma to form 50/50 joint venture for commercialization of rivoceranib for gastric cancer in Middle East and North Africa and India Elevar Therapeutics Neopharma Payment unspecified 10/3/19
Emerson to manufacture Biokier’s BKR-017 in type 1 diabetes patients Emerson Resources Inc. Biokier Inc. Payment unspecified 10/1/19
Undislcosed company to research, develop and commercialize nucleic acid therapies using Entos' Fusogenix non-viral delivery technology Entos Pharmaceuticals Inc. Undisclosed $109.00 10/2/19
Exagen to support clinical study of Horizon’s pegloticase with methotrexate using Avise MTX test Exagen Diagnostics Inc. Horizon Therapeutics plc Payment unspecified 10/24/19
Excelera to distribute Pfizer’s Vyndaqel and Vyndamax for transthyretin amyloid cardiomyopathy Excelerarx Corp. Pfizer Inc. Payment unspecified 10/3/19
Adaptate Biotherapeutics spins out from Gammadelta Therapeutics to focus on gamma delta T-cell-based cell therapy products Gammadelta Therapeutics Ltd. Adaptate Biotherapeutics Ltd. Payment unspecified 10/16/19
GC Pharma to market Merck's Glucophage for diabetes in Korea GC Pharma Ltd. Merck Biopharma Co. Ltd. Payment unspecified 10/11/19
Bavarian Nordic to acquire Glaxosmithkline's Rabipur and Encepur against rabies and tick-borne encephalitis worldwide Glaxosmithkline plc Bavarian Nordic A/S $884.83 10/21/19
Glenmark Holding to spin-off Ichnos Sciences for development of five clinical-stage assets in oncology, autoimmune disease and pain using bispecific antibodies based on the T-cell receptor platform Glenmark Holding SA Ichnos Sciences Inc. Payment unspecified 10/15/19
Gilead to use Glympse’s Glympse Inside biomarkers to study treatments in nonalcoholic steatohepatitis patients Glympse Bio Inc. Gilead Sciences Inc. Payment unspecified 10/28/19
Great Bay Bio and Guangzhou Boji Medical to form joint venture to develop GBB-101 against anemia Guangzhou Boji Medical & Biotechnological Co. Ltd. Great Bay Bio Payment unspecified 10/18/19
Guangzhou Institutes of Biomedicine and Health (GIBH) to spinout Legion Pharma for the development of anti-tuberculosis therapies discovered through a partnership between the University of Birmingham and GIBH Guangzhou Institutes of Biomedicine and Health Legion Pharma Payment unspecified 10/23/19
Leadxpro and Lundbeck to research on small molecule structure-based drug discovery of membrane protein targets H Lundbeck A/S Leadxpro AG Payment unspecified 10/7/19
Medavate to acquire Neocart assets from Histogenics Histogenics Corp. Medavate Corp. $7.00 5/8/19
Hitgen to discover small molecule therapeutics for Galapagos' targets Hitgen Ltd. Galapagos NV Payment unspecified 10/16/19
Shionogi and Hsiri Therapeutics to research and develop therapeutics for nontuberculous mycobacterial diseases and tuberculosis Hsiri Therapeutics Inc. Shionogi & Co. Ltd. Payment unspecified 10/11/19
Foundation Medicine to support Ideaya's phase I/II clinical trial of IDE-196 against metastatic uveal melanoma by enabling the Foundationone CDx genomic approach Ideaya Biosciences Inc. Foundation Medicine Inc. Payment unspecified 10/8/19
Immugenyx LLC partnered with an undisclosed global pharmaceutical company to develop humanized mice as a tool for drug development and testing Immugenyx LLC Undisclosed global pharmaceutical company $0.08 10/23/19
Alexion to acquire Immune Pharma's bertilimumab for inflammatory diseases Immune Pharmaceuticals Inc. Alexion Pharmaceuticals Inc. Payment unspecified 10/23/19
Ph Pharma and Immunome to discover and develop antibody drug conjugates against oncology targets Immunome Inc. Ph Pharma Co. Ltd. $100.00 10/21/19
Innovent Biologics and Hutchison China Meditech expanded the agreement testing sintilimab and surufatinib in solid tumors Innovent Biologics Inc. Hutchison China Meditech Ltd. Payment unspecified 10/10/19
Insilico Medicine and Jiangsu Chia Tai Fenghai Pharmaceutical to develop therapeutics against triple-negative breast cancer using artificial intelligence drug discovery platform Insilico Medicine Inc. Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd. $200.00 10/9/19
Chemdiv and Insilico Medicine to provide drug discovery solutions by combining artificial intelligence techniques with an integrated drug discovery shared risk platform Insilico Medicine Inc. Chemdiv Inc. Payment unspecified 10/16/19
Akero and Insphero to characterize the effects of AKR-001 on liver cells using three-dimensional insight human liver disease platform for nonalcoholic steatohepatitis and non-alcoholic fatty liver disease Insphero AG Akero Therapeutics Inc. Payment unspecified 10/3/19
Neptune Wellness and IFF to codevelop hemp derived cannabidiol products in the U.S. International Flavors & Fragrances Inc. Neptune Wellness Solutions Inc. Payment unspecified 10/2/19
Roche to evaluate the Inxmed's IN-10018 in combination with Cobimetinib against melanoma Inxmed (Shanghai) Co. Ltd. Roche Holding AG Payment unspecified 10/17/19
ITG Isotope Technologies Garching to enter supply agreement with Nordic Nanovector for the medical radioisotope no-carrier-added Lutetium-177 (177Lu) endolucinbeta to support research and development, clinical and commercial supply of Betalutin ITG Isotope Technologies Garching GmbH Nordic Nanovector ASA Payment unspecified 10/8/19
Neumentum to develop Janssen's JNJ-10450232 for pain worldwide Janssen Pharmaceutica NV Neumentum Inc. Payment unspecified 10/10/19
Seneca Biopharma to enter non-binding term sheet to develop and commercialize Qyuns Therapeutics' monoclonal antibodies to treat autoimmune diseases worldwide Jiangsu Qyuns Therapeutics Co. Ltd. Seneca Biopharma Inc. Payment unspecified 10/30/19
Jubilant Radiopharma to distribute Q Biomed's Metastron for cancer pain in the U.S. Jubilant Radiopharma Q Biomed Inc. Payment unspecified 10/3/19
Biocon to develop and commercialize Just Evotec's biosimilar asset Just-Evotec Biologics Biocon Ltd. Payment unspecified 10/10/19
Crispr and KSQ to use intellectual property related to cell therapy programs for editing gene targets identified using Crispromics for oncology KSQ Therapeutics Crispr Therapeutics AG Payment unspecified 10/15/19
Lannett to distribute Respirent's generic Advair Diskus for asthma and chronic obstructive pulmonary disease in the U.S. Lannett Co. Inc. Respirent Pharmaceuticals Co. Ltd. Payment unspecified 10/1/19
Leo Pharma and Foamix Pharmaceuticals settled patent litigation related to Finacea with Teva Leo Pharma A/S Teva Pharmaceutical Industries Ltd. Payment unspecified 10/21/19
Lonza Biologics to manufacture Cellectis SA's allogeneic universal CAR T-cell candidates targeting hematological malignancies Lonza Biologics Cellectis SA Payment unspecified 10/2/19
Lonza Group to manufacture Prevail Therapeutics' PR-001 and PR-006 for neurodegenerative disease Lonza Group AG Prevail Therapeutics Inc. Payment unspecified 10/8/19
Lonza Group to manufacture Mesoblast's remestemcel-L for pediatric steroid-refractory acute graft-vs.-host disease Lonza Group AG Mesoblast Ltd. Payment unspecified 10/17/19
GSK to use Lyell’s technologies to enhance benefit/risk profile of cancer cell therapies Lyell Immunopharma Inc. Glaxosmithkline plc Payment unspecified 10/8/19
Sotio to receive an option to codevelop Maverix’s MVX-5005 and related compounds for cancer in Europe Maverix Oncology Inc. Sotio AS $138.00 10/14/19
Editas to use Maxcyte's technology and instruments to develop engineered cell medicines for cancer and hematological diseases Maxcyte Inc. Editas Medicine Inc. Payment unspecified 10/7/19
MB Research Labs to conduct IND studies for Nanoviricides' NV-HHV-101 in dermal sensitization and ocular irritation Mb Research Laboratories Inc. Nanoviricides Inc. Payment unspecified 10/31/19
Aetion to integrate Evidence Platform with Mckesson's Iknowmed for oncology research Mckesson Corp. Aetion Inc. Payment unspecified 10/15/19
Medicasafe to provide Amneal's generic version of Suboxone through data-generating medication system for opioid dependence Medicasafe Inc. Amneal Pharmaceuticals Inc. Payment unspecified 10/3/19
Medigen to use Medinet's immune cell Gamma Delta T cell to develop cell therapies against cancer in Taiwan Medinet Co. Ltd. Medigen Biotechnology Corp. Payment unspecified 10/7/19
Immunoqure and Memo Therapeutics to develop autoantibodies from APS-1 memory B cells using Dropzylla technology Memo Therapeutics AG Immunoqure Ag Payment unspecified 10/2/19
Novartis to use Microsoft data and Artificial Intelligence to transform medicine Microsoft Corp. Novartis AG Payment unspecified 10/1/19
Abbott to commercialize Mithra's Myring for contraception in China Mithra Pharmaceuticals Abbott Laboratories Payment unspecified 10/14/19
Mayne to use and commercialize Mithra's Estelle as a contraceptive in the U.S. Mithra Pharmaceuticals SA Mayne Pharma Group Ltd. $295.00 10/1/19
Dong Koo to commercialize Moberg's MOB-015 against onychomycosis in Republic of Korea Moberg Pharma AB Dong Koo Pharmaceutical Co. Ltd. Payment unspecified 10/21/19
Orphan Pacific to commercialize MSD's Diazoxide for hypoglycemia in Japan MSD Japan Orphan Pacific Inc. Payment unspecified 10/15/19
Gedeon Richter to develop and commercialize Mycovia's VT-1161 for recurrent vulvovaginal candidiasis in Europe, Latin America, Australia, Russia and other Commonwealth of Independent States countries Mycovia Pharmaceuticals Inc. Gedeon Richter plc Payment unspecified 10/16/19
Next Oncology to provide PDX models to Crown Bioscience for preclinical drug development against cancer Next Oncology Inc. Crown Bioscience Inc. Payment unspecified 10/28/19
Yakult Honsha to co-promote Nihon Servier's liposomal irinotecan against pancreatic cancer in Japan Nihon Servier Co. Ltd. Yakult Honsha Co. Ltd. Payment unspecified 10/8/19
Recordati to acquire Novartis' Signifor, Signifor LAR and LCI-699 for Cushing’s disease and acromegaly Novartis AG Recordati SpA $390.00 10/23/19
Eyevance Pharmaceuticals acquired Tobradex ST for steroid-responsive inflammatory ocular conditions and Natacyn (natamycin ophthalmic suspension) 5%, for the treatment of fungal blepharitis, conjunctivitis and keratitis from Novartis AG Novartis AG Eyevance Pharmaceuticals Inc. Payment unspecified 10/17/19
Bluebird Bio and Novo Nordisk to develop in vivo genome editing therapies for hemophilia and severe genetic diseases Novo Nordisk A/S Bluebird Bio Inc. Payment unspecified 10/9/19
Eisai and Numab to discover and develop multi-specific antibody immunotherapies for cancer using Numab’s Match platform worldwide Numab Therapeutics AG Eisai Co. Ltd. Payment unspecified 10/1/19
Oncosec Medical to receive a $30M investment from Grand Decade Developments in exchange for an exclusive license to develop, manufacture, commercialize Oncosec’s current and future products, including Tavo and Visceral Lesion Applicator (VLA), in greater China and 35 other Asian countries Oncosec Medical Inc. Grand Decade Developments Ltd. $30.00 10/11/19
Veriton to commercialize Orphelia Pharma's Kigabeq for infantile spasms in the U.K. Orphelia Pharma SA Veriton Pharma Ltd. Payment unspecified 10/29/19
Ovizio to supply Iline F microscope and Bioconnect system to Celgene to automate the manufacturing of engineered T-cell investigational products Ovizio Imaging Systems Nv/Sa Celgene Corp. Payment unspecified 10/22/19
Pandion and Astellas to develop and commercialize immunomodulators for type 1 diabetes and multiple pancreatic autoimmune worldwide Pandion Therapeutics Inc. Astellas Pharma Inc. $795.00 10/30/19
PDS Biotechnology modified the clinical trial collaboration agreement with a subsidiary of Merck to evaluate the combination of PDS-0101 with Keytruda (pembrolizumab) for recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 infection PDS Biotechnology Corp. Merck & Co. Inc. Payment unspecified 10/3/19
Astrazeneca to use Petagene's Petasuite software cloud for the integration of genomics into its drug discovery platform Petagene Ltd. Astrazeneca plc Payment unspecified 10/16/19
Pharmahemp to distribute Allied's cannabidiol extract products in the European and Asian markets Pharmahemp d.o.o Allied Corp. Payment unspecified 10/2/19
Specialised Therapeutics to commercialize Pharmamar's Yondelis in Australia, New Zealand and South East Asia against advanced sarcoma Pharmamar SA Specialised Therapeutics Asia Pte. Ltd. Payment unspecified 10/14/19
Luina Bio to manufacture LNC Therapeutics' live biotherapeutic product to treat obesity and metabolic disorders Pharmasynth Pty Ltd. LNC Therapeutics SA Payment unspecified 10/22/19
Casi to develop and market Pharmathen’s long-acting injectable microsphere in China for the treatment of acromegaly and for the control of symptoms associated with certain neuroendocrine tumors Pharmathen SA Casi Pharmaceuticals Inc. Payment unspecified 10/29/19
Novartis to develop and commercialize Pliant’s PLN-1474 for nonalcoholic steatohepatitis and fibrotic diseases worldwide Pliant Therapeutics Inc. Novartis AG $80.00 10/23/19
Premier to supply Amphastar's seven shortage drugs in the U.S. Premier Inc. Amphastar Pharmaceuticals Inc. Payment unspecified 10/8/19
Prometheus and Takeda to discover, develop and commercialize therapies and companion diagnostics for inflammatory bowel disease worldwide Prometheus Biosciences Inc. Takeda Pharmaceutical Co. Ltd. $420.00 10/3/19
Brii Biosciences to develop and commercialize Qpex Biopharma's portfolio for multi-drug resistant gram-negative infections in mainland China, Hong Kong, Macau and Taiwan Qpex Biopharma Inc. Brii Biosciences Inc. Payment unspecified 10/22/19
An undisclosed South American laboratory to enter negotiations to develop and commercialize Quantum Genomics' firibastat for arterial hypertension in Latin America Quantum Genomics Corp. Undisclosed South American laboratory Payment unspecified 10/7/19
Pegbio to evaluate Quiapeg's Uni-Qleaver technology for biobetters Quiapeg Pharmaceuticals Ab Pegbio Co. Ltd. Payment unspecified 10/23/19
Medison Pharma to commercialize Rigel's fostamatinib for all indications in Canada and Israel Rigel Pharmaceuticals Inc. Medison Pharma Ltd. $40.00 10/1/19
Bayer and Riken Innovation to discover therapeutics across indications Riken Innovation Co. Ltd. Bayer AG Payment unspecified 10/9/19
Selexis to develop Tenebio's human heavy-chain antibodies to treat multiple myeloma, lymphoma and prostate cancer Selexis SA Teneobio Inc. Payment unspecified 10/17/19
Carna Biosciences to use Seranovo's DES formulation platform to develop oral formulation of kinase inhibitor Seranovo BV Carna Biosciences Inc. Payment unspecified 10/4/19
Novogene to develop companion diagnostics for Shenzhen Chipscreen's chiauranib against small cell lung cancer Shenzhen Chipscreen Biosciences Ltd. Novogene Co. Ltd. Payment unspecified 10/8/19
Rain Therapeutics to use Sign Path's Correqt technology to develop Tarlox against cancer Signpath Pharma Inc. Rain Therapeutics Inc. $78.00 10/31/19
Skyflair Asia to distribute Peptonic medical's Vagivital for vaginitis in Hong Kong Skyflair Asia Peptonic medical AB Payment unspecified 10/31/19
Alexion to develop and co-promote Stealth's elamipretide for mitochondrial diseases in the U.S. Stealth Biotherapeutics Inc. Alexion Pharmaceuticals Inc. $45.00 10/10/19
Goldfinch to develop and commercialize Takeda's CB1 monoclonal antibody for rare and metabolic kidney diseases worldwide Takeda Pharmaceutical Co. Ltd. Goldfinch Bio Inc. Payment unspecified 10/3/19
Acino to acquire Takeda's OTC and prescription pharmaceutical assets in Near East, Middle East and Africa Takeda Pharmaceutical Co. Ltd. Acino Holding AG $200.00 10/15/19
Tannergap to distribute Napo Pharmaceuticals' Mytesi on a named-patient basis outside of the U.S., Canada and Israel Tannergap Inc. Napo Pharmaceuticals Inc. Payment unspecified 10/31/19
Tedor Pharma to manufacture Sequential's triple combination drug product for the short-term treatment of transient insomnia Tedor Pharma Inc. Sequential Medicine Ltd. Payment unspecified 10/16/19
GE Healthcare to commercialize Theragnostics' Galliprost for prostate cancer worldwide Theragnostics Ltd. GE Healthcare Inc. Payment unspecified 10/9/19
Menarini to commercialize Tillotts' Asacol for inflammatory bowel disease in People's Republic of China Tillotts Pharma AG The Menarini Group Payment unspecified 10/28/19
Vaxess and GC Pharma to develop and commercialize influenza vaccine using mimix smart release patch technology smart release patch technology in the U.S., Europe and South Korea Vaxess Technologies Inc. GC Pharma Ltd. Payment unspecified 10/16/19
Cipla to acquire Venus Remedies' Elores in India Venus Remedies Ltd. Cipla Ltd. Payment unspecified 10/17/19
Mitsubishi to develop and commercialize Viela Bio's inebilizumab for neuromyelitis optica spectrum disorder in Japan and other Asian regions Viela Bio Inc. Mitsubishi Tanabe Pharma Corp. $30.00 10/8/19
Hope Biosciences to use Virtrial's telehealth platform for autologous, adipose-derived culture expanded mesenchymal stem cell study to treat spinal cord injury/disorder Virtrial LLC Hope Biosciences Inc. Payment unspecified 10/9/19
Y-Biologics and Pascal Biosciences to discover and develop bispecific antibodies for leukemia Y-Biologics Inc. Pascal Biosciences Inc. Payment unspecified 10/29/19

No Comments